E-therapeutics Plc
ETXPF · OTC
1/31/2025 | 7/31/2024 | 1/31/2024 | 7/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -67.1% | -69.4% |
| R&D Expenses | $9 | $6 | $5 | $5 |
| G&A Expenses | $2 | $2 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $7 | $7 | $7 |
| Operating Income | -$11 | -$8 | -$7 | -$7 |
| % Margin | – | – | -4,319% | -4,356.3% |
| Other Income/Exp. Net | $1 | $2 | $0 | $0 |
| Pre-Tax Income | -$10 | -$5 | -$6 | -$7 |
| Tax Expense | $2 | $1 | -$1 | -$1 |
| Net Income | -$9 | -$6 | -$6 | -$6 |
| % Margin | – | – | -3,526.6% | -3,496.2% |
| EPS | -0.011 | -0.011 | -0.01 | -0.01 |
| % Growth | 2.6% | -19.4% | 0.2% | – |
| EPS Diluted | -0.011 | -0.011 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 778 | 704 | 584 | 583 |
| Weighted Avg Shares Out Dil | 778 | 704 | 584 | 583 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | -$0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$7 | -$6 | -$6 |
| % Margin | – | – | -3,900.6% | -3,972.5% |